The Institut Jantung Negara in Kuala Lumpur, Malaysia, has become the first Asian center to join the Xplore-I trial. Three children have been successfully implanted with Xeltis’ bioabsorbable pulmonary heart valve this week and are currently recovering at the hospital.
The primary objective of the trial is to assess the survival rate of patients undergoing Right Ventricular Outflow Tract (RVOT) reconstruction at six months following implantation of the bioabsorbable heart valve. All patients involved in the trial to date had been previously implanted with currently available heart valve prostheses and needed reoperation just a few years afterwards.
“The interest of physicians around the world for our Xplore-I trial shows there is a clear need to find alternative solutions to current treatment options. Cardiovascular restoration via ETR has the potential to drastically improve treatment paradigms,” said Laurent Grandidier, Xeltis CEO.
Click here for the recent announcement on Xplore-I trial initiation.
